Fully agree that a human challenge trial *would not* have resulted in an authorized/approved vaccine any sooner.

Disagree that every smart person was recommending a human challenge trial to speed up the approval process. 1/
It is not a simple undertaking to establish a human challenge model, particularly with a novel virus for which the pathophysiology is not well-understood and where a targeted therapeutic is not available for what could be a lethal disease. 2/
Safety is obviously a major issue to be worked out, and this is tightly linked to ethical considerations. Beyond this, it takes time to determine the baseline infection/disease parameters that you hope to modify with the vaccine. 3/ thelancet.com/journals/lanin…
Safety considerations would argue for use of an attenuated strain. But if the goal is to use the model for licensure, then you want to mirror the disease to the greatest degree possible. A difficult balance for a virus we don't fully understand, and again, time is against us. 4/
These are just a few of the issues that would need to be worked out. But most importantly, no regulatory authority would license a vaccine on the basis of human challenge in the midst of a raging pandemic in which it's easy to accrue cases, ref Pfizer & Moderna trials. 5/
Having said this, human challenge trials can play a very important role in vaccine development if the safety and ethical considerations can be worked out. 6/

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Rajeev Venkayya MD

Rajeev Venkayya MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @rvenkayya

29 Nov
@bnallamo Fair question. Here are a few thoughts from a non-regulator. First, @US_FDA, led by Peter Marks and Operations Warp Speed, led by Moncef Slaoui, recognize that every day matters for HCWs and high-risk groups and are moving with extraordinary speed. 1/
@bnallamo @US_FDA An EUA (Emergency Use Authorization) for a vaccine is not the same as a therapeutic, given that the vaccine is being given to subgroups of people who are “healthy” and may or may not be exposed to the virus. The bar for safety & efficacy data is therefore higher than for Rx. 2/
@bnallamo @US_FDA The dataset is very large (44K participants), and thorough analyses of safety & efficacy take time. Moreover, the studies aren’t powered to conclude efficacy in the subgroups being considered for EUA, yet convincing benefit-risk assessments for those groups need to be shown. 3/
Read 10 tweets
12 Nov
THREAD
In light of the Pfizer #vaccine news, a natural question is whether it's feasible to develop “better” #COVID19 vaccines after the first ones are approved?

The answer is yes. It can be complicated but there are ways to do it. 1/

First let’s break this down into three questions:
▪️ Why might we want better vaccines?
▪️ Why would it be hard to study new vaccines?
▪️ What are the options for doing this? 2/
WHY MIGHT WE WANT BETTER VACCINES?

After we’ve seen full Phase 3 datasets on the first vaccines, we may desire better efficacy in certain populations, longer protection, greater impact on transmission, improved dosing schedule, or an improved safety profile. 3/
Read 24 tweets
9 Nov
This is very good news indeed, and the *potential* implications go well beyond the @pfizer #COVID19 vaccine.

While we just have the press release, it's worth reviewing what this *could* mean for the pandemic and beyond. A thread. 1/

@BioNTech_Group
First, it shows vaccines *can* prevent COVID illness in humans, and it validates the spike protein target. We didn't know these things before today, and it's good news for all #COVID19 vaccines in development. 1/
Second, the early efficacy is quite high, although it may wane over time. We can't say anything about duration of protection yet, but it helps to start from a high level of efficacy. Higher efficacy reduces the uptake needed to significantly dampen virus transmission. 2/
Read 8 tweets
23 Oct
To be clear, it's not impossible, and OWS surely has assumptions to support this. And yes we must be ambitious.

But many will assume and/or communicate that these *targets* are what they can *expect* to happen, when there are many unknowns and execution risks. 1/
A few big ones: (1) we don't have *any* efficacy data, incl in elderly; (2) manufacturing scale-up is complex and delays very common; (3) first-time cold-chain, distribution and logistics; and (4) presumably more than one vaccine needs to succeed for this to happen; etc. 2/
Read 5 tweets
12 Oct
Yes the first COVID vaccines will face challenges, but the overall situation is quite promising. Thread.

First, we can’t predict how good the first vaccines will be - we need Phase 3 data. We shouldn’t assume they will be very effective, poorly-effective, or “so-so.” 1/
It's true that some "second wave" vaccines will be better, because they're intended to address gaps, but that doesn't mean the first vaccines won't be good.

Second, don't underestimate complexity of aligning multiple Phase 3 vaccine programs around a single master protocol. 2/
This would have delayed the Phase 3 trials, with a human cost. It's not just about companies aligning with each other and regulators - it requires rigorous matching of the placebo arm with multiple vaccine arms to avoid reaching the wrong conclusions about efficacy. 3/
Read 8 tweets
26 Apr
This is a thread on the use of antibody tests (serology) to gauge individual risk for COVID-19 infection. It's triggered by the recent @WHO guidance and the push for "immunity certificates" to get people back into the workplace. @jeremyfarrar @laurie_garrett @mvankerkhove 1/8
The science isn’t there, and it could get us into trouble for two reasons: partial immunity and risk perception. A history of COVID-19 and/or circulating antibodies may not translate to complete protection in all individuals. This is the case for circulating coronaviruses. 2/8
We’ll likely see spectrum of protection, with many people having "partial immunity," meaning that they can be reinfected but with less severe symptoms or no symptoms at all. These individuals may "shed" lower amounts of virus but could still infect others. 3/8
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!